ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0512

Factors Associated with Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-year Follow-up of the DESIR Cohort
Abstract Number: 1127

Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis
Abstract Number: 0488

Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity
Abstract Number: 2497

Factors Influencing Time to Diagnosis in U.S. Patients with Systemic Lupus Erythematosus
Abstract Number: 1221

Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM)
Abstract Number: 1722

Fate-mapping of Synovial Monocytes and Macrophages
Abstract Number: 1381

Fatigue and Associated Factors in Patients with Primary Sjogren’s Syndrome Compared to Secondary Sjogren’s Syndrome
Abstract Number: 1749

Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis
Abstract Number: 0947

Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis
Abstract Number: 2398

FDG Uptake in Limb Arteries at Diagnosis of Giant Cell Arteritis and Risk of Relapse: An Observational Cohort Study
Abstract Number: 1869

FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients
Abstract Number: 0320

Feasibility and Acceptability of Geniculate Artery Embolization for the Treatment of Painful Knee Osteoarthritis
Abstract Number: 2092

Feasibility and Efficacy of Culturally Appropriate Spanish Language-First Patient Education for Rheumatoid Arthritis
Abstract Number: 0132

Feasibility of a Real-Time Risk Model to Identify Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease
Abstract Number: 0231

Febuxostat Dose Requirement for Achieving Target Serum Urate Levels According to Renal Function: A Retrospective Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].